Development of Novel Biotherapeutics
Developability, Enhanced Product Properties and Therapeutic Application
7-8 November 2013
Preliminary Agenda
This 1 ½ day conference with additional plenary session late morning before the conference opens focuses on measures to enhance product properties such as avoidance of aggregation, optimization of stability, PK, affinity and targeting, and improved manufacturability. It provides an opportunity to hear the experiences of the pioneers that have products in pre-clinical and clinical development. It will focus on the challenges of designing and interpreting pre-clinical toxicology and safety studies, and on decision points for moving into the clinic. Don’t miss the dinner short course on Troubleshooting and Engineering of Antibody Constructs.
PLENARY SESSION
Overview of Trastuzumab
Martine Piccart, Head, Medical Oncology, Jules Bordet Institute, Chair, ESMO (European Society for Medical Oncology)
Antibody-Drug Conjugates: From Bench to Bedside and Back
Robert Lutz, Ph.D., Vice President, Translational Research & Development, ImmunoGen, Inc.
In silico Prediction of Degradation Hotspots in Antibody Variable Regions
Hubert Kettenberger, Ph.D., Principal Scientist, Large Molecule Research, Roche Pharma Research and Early Development (pRED)
Unique in silico Tools for Prediction of Propensity to Aggregate and for Viscosity for Monoclonal Antibodies and Therapeutic Proteins
Bernhard Helk, Ph.D., Head, Physico-Chemical Analysis, Novartis Pharma AG
Engineering Aggregation Resistance in IgGs based on Lessons Learned from Comparative Expression
Jonas V. Schaefer, Ph.D., High-Throughput Laboratory, Biochemistry, University of Zurich
Rapid Design of Optimized Site-Specific ADCs and Manufacture by Cell-Free Protein Synthesis
Trevor J. Hallam, Ph.D., CSO, Research & Development, Sutro Biopharma, Inc.
Optimization of Bispecific DART Proteins for Clinical Use
Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics, Inc.
CTLA4 – Fc Fusion: Engineering for Increased Affinity to CD80 and CD86 for the Treatment of Inflammatory Diseases
David Lowe, Ph.D. Fellow, Research & Development, Antibody Discovery and Protein Engineering, MedImmune LLC
Development of Leptin and Interleukin 22 Antagonists and Potential Use in Therapy of Cachexia and Autoimmune Diseases: A Novel Approach for Development of High-Affinity Cytokine Antagonists
Arieh Gertler, Ph.D., Professor, Institute of Biochemistry, Food Science and Nutrition, Hebrew University in Jerusalem
RG7116, A Novel Therapeutic Antibody that Locks HER3 in the Closed Conformation, Potently Blocks HER3 Signaling, and is Optimized for Immune Effector Activation
Birgit Bossenmaier, Ph.D., Principle Scientist, Discovery Oncology, Roche
Targeted Fas-Mediated Treatment of B-Cell Lymphoma by Hexameric CTLA4-FasL
Noam Shani, KAHR Medical, Hadassah Medical Center, Jerusalem
Pro-Apoptotic and Anti-Angiogenic Tumor Therapy Approaches with Novel DARPin Formats
Ignacio Dolado, Ph.D., Program Leader, Research Oncology, Molecular Partners AG
Selecting Lead DVD-Ig Candidates for Clinical Development
Tariq Ghayur, Ph.D., Senior Research Fellow, Abbvie
Exploring Antibody Domains as Effective Candidate Therapeutics
Steven Grant, Ph.D., Manager, Biopharm Discovery, Biopharm Research & Development, GSK (Domantis)
Plant-Derived Pharmaceuticals; A New Era for Medicine
Kathleen Hefferon, Ph.D., Scientist, Cell and Systems Biology, University of Toronto